Abstract
Sophora alopecuroides L. empyreumatic oil (SoA oil) shows therapeutic potential for psoriasis and eczema but is limited by poor skin permeability and formulation challenges. This study developed a nanoemulsion (NE) gel to overcome these hurdles. Optimized using pseudo-ternary phase diagrams, the NE featured a mean droplet size of 53.27 nm and a zeta potential of -38.13 mV. Incorporation into a 2% carbomer 940 gel enhanced viscoelasticity. In vitro tests showed superior skin permeability and higher cutaneous retention of the marker oxymatrine compared to raw oil. In vivo rabbit tests confirmed the NE gel eliminated the moderate irritation caused by raw SoA oil. Furthermore, the NE demonstrated significantly enhanced anti-biofilm activity against Staphylococcus aureus and MRSA, highlighting its potential for treating biofilm-associated dermatological infections.
Introduction
Sophora alopecuroides L. (SoA) oil is a traditional herbal remedy valued for its potent anti-inflammatory and antibacterial properties. It is a promising candidate for treating chronic skin conditions such as psoriasis and eczema. However, clinical application is hindered by several practical challenges: the oil has poor skin permeability, a dark color, a pungent odor, and a tendency to adhere to wounds, which reduces patient compliance.
Moreover, many dermatological infections are complicated by the formation of biofilms—resilient bacterial communities encased in a protective extracellular matrix. Conventional treatments often fail to penetrate these barriers. This research aimed to develop a nanotechnology-driven delivery system capable of bypassing the skin's stratum corneum while enhancing the oil's efficacy against these resilient bacterial colonies.
Methodology
The research team employed a nanoemulsion (NE) strategy to disperse the SoA oil into nanoscale droplets within an aqueous base.
Formulation and Optimization
Pseudo-ternary phase diagrams were utilized to identify the optimal ratio of surfactants (Cremophor EL) and co-surfactants (PEG 400) to ensure a stable nanoemulsion region. To transition the liquid NE into a form suitable for topical application, it was incorporated into a Carbomer 940 (CP940) gel matrix. This formulation was compared against other gelling agents, such as HPMC and CMC-Na, through rheological studies to ensure ideal viscosity and thixotropic behavior.
Characterization and Tracking
The NE was characterized for droplet size, polydispersity index (PDI), and zeta potential. To track the delivery efficiency, oxymatrine, a primary alkaloid found in SoA, was used as a chemical marker. Skin permeability and retention were assessed in vitro using Franz diffusion cells with Kunming rat skin, and oxymatrine levels were quantified via HPLC.
Biological Assays
The safety profile was evaluated through in vivo skin irritation tests on rabbit dorsal skin. Anti-biofilm efficacy was tested against Staphylococcus aureus (ATCC 6538) and Methicillin-resistant S. aureus (MRSA, ATCC 43300) to measure both biofilm inhibition and the clearance of mature biofilms.
Results and Discussion
Physical Properties and Skin Penetration
The optimized nanoemulsion achieved a mean droplet size of 53.27 nm with a PDI of 0.236. This small size is critical for providing a large surface area for drug release and allowing droplets to navigate the skin's lipid bilayers effectively. The NE gel demonstrated a cutaneous retention of oxymatrine at 19.8 μg/cm², which is nearly 4.5 times higher than that of raw SoA oil (4.4 μg/cm²).
Safety and Irritation
A significant finding was the improvement in the safety profile. Raw SoA oil caused moderate skin irritation in rabbits, scoring a 4 after 72 hours. In contrast, both the NE and the NE gel formulations resulted in zero irritation (score of 0). Encapsulating the oil within nano-droplets appears to shield the skin from the harsher components of the raw extract.
Anti-Biofilm Efficacy
The NE formulations showed superior performance against bacterial biofilms:
- Inhibition: At 12.50 mg/mL, the NE and the gel achieved inhibition rates of 81.7% and 82.1% against S. aureus, respectively, compared to 78.3% for the raw oil.
- Clearance: Against MRSA, the NE and the gel achieved clearance rates of 42.7% and 43.9% respectively at 12.50 mg/mL, significantly outperforming the raw oil's 31.9% (P < 0.0001).
- Low Concentration Performance: The NE was particularly effective at low concentrations (0.09766 mg/mL), showing an 8.9% inhibition rate compared to just 2.0% for the raw oil.
The surfactant components of the NE likely assist in disrupting the protective extracellular polymeric substance (EPS) matrix of the biofilm, allowing the active herbal components to reach the bacteria.
Conclusion
The development of a nanotechnology-driven nanoemulsion gel represents a significant advancement in the topical delivery of Sophora alopecuroides L. empyreumatic oil. By enhancing skin penetration and eliminating irritation, this formulation addresses the primary barriers to the clinical use of SoA oil. Its superior anti-biofilm activity, particularly against MRSA, suggests it could be a potent tool in treating complex, biofilm-associated dermatological infections. Future work should focus on long-term stability and in vivo efficacy in infected wound models.
Summary updated